Karkinos Healthcare

What Karkinos Healthcare does

Karkinos Healthcare is a technology-driven, purpose-built oncology platform headquartered in Mumbai that operates a Distributed Cancer Care Network (DCCN) connecting community screening, advanced diagnostics, genomic sequencing, treatment delivery and remote care navigation across a partner hospital and lab footprint spanning 12 Indian states and roughly 80 cancer care centres. Its core product is the Karkinos Platform — a FHIR-compliant, AI/ML-enabled digital backbone that aggregates clinical, pathology, radiology, molecular and treatment data into a single longitudinal patient record, integrates with India's Ayushman Bharat Digital Mission (ABHA), and routes patients through risk assessment, screening, molecular tumour boards, day-care chemotherapy, radiation coordination and post-treatment follow-up via a centralised Command Center staffed largely by care navigators. The portfolio is modularised across Advanced Diagnostics Labs (HPV DNA, KGT genetic testing, CardioSeq 223-gene NGS panel, WGS, pathology), a Women's Wellness programme, Early Detection screening, Sequencing-as-a-Service, a hospital-based Treatment network, an Expert Opinion second-opinion service, the Karkinos mobile app, the k-Vani content platform and the CIRP community outreach programme.

Karkinos generates revenue through five reinforcing streams: fee-for-service diagnostics and genomic testing, managed-services-style treatment delivery and hospital commissioning across the DCCN partner network, large-scale community and population-screening contracts (often NGO/government-aligned), tele-oncology and second-opinion fees, and clinical/research collaborations such as the Bharat Cancer Genome Atlas. Pricing is quote-based rather than published; transactions flow through direct-to-consumer (app, website, Command Center), enterprise/hospital commissioning, channel-partner DCCN expansion, and community-led outreach via KareMitras. Following its 2024 acquisition by Reliance Industries, Karkinos operates as a 100% step-down subsidiary and continues to leverage early backing from the Tata Group (Ratan Tata), Rakuten, Endiya Partners and Mayo Clinic to scale cancer care delivery across India.

Name

Karkinos Healthcare

Legal name

Karkinos Healthcare Private Limited

Website

https://karkinos.in

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

251–500 employees

Short description

Karkinos Healthcare is a Mumbai-based, technology-driven oncology platform operating a Distributed Cancer Care Network of 80 cancer care centres and advanced diagnostics labs across 12 Indian states, delivering AI-enabled screening, genomic sequencing, treatment and remote care navigation to cancer patients and partner hospitals.

Ownership category

akta.pro rank

Product category

Oncology Care Services

NAICS

Medical and Diagnostic Laboratories (62151), Computer Systems Design Services (541512)

SIC

Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)

akta.pro primary industry

Oncology Telemedicine Platforms (HLALAGAH)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Oncology care services
• Cancer diagnostics
• Genomic sequencing
• Preventive cancer screening
• Tele-oncology

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostics & Genomic Testing Services: Fee-for-service revenue from advanced diagnostics labs spanning HPV DNA testing, genetic tests, KGT (Karkinos Genetic Test), CardioSeq 223-gene NGS panel, Whole Genome Sequencing (WGS), and routine pathology – consumption-based per-test billing.
2. Treatment & Care Delivery through DCCN: Revenue from oncology treatment delivered across the Distributed Cancer Care Network, including day-care chemotherapy, radiation coordination, surgery through partner hospitals, and end-to-end patient navigation via the Command Center – effectively managed services across the partner hospital footprint.
3. Community Cancer Screening & Outreach Programmes: Revenue from large-scale population screening contracts and women wellness / HPV screening programmes delivered at community and rural level, often in collaboration with NGOs (e.g., IVDP at Krishnagiri) and partner hospitals (Sir HN Reliance Foundation Hospital).
4. Digital Second-Opinion / Tele-oncology Services: Fee-based digitally-coordinated second opinion and teleconsultation services to patients and physicians, with explicit second-opinion pricing through expertopinion.live.karkinos.in and integration into oncology care pathways.
5. Hospital Commissioning & Clinical Operations Services: Revenue from commissioning cancer centres at partner hospitals, providing centralized clinical expertise, SOPs, training and operational management for cancer service lines under long-term partnerships.

Pricing tiers

Go-to-market motion4 records

Core offering

Karkinos Healthcare operates a technology-led, end-to-end oncology platform that delivers cancer care from risk assessment and early screening through diagnostics, genomic sequencing, treatment, and post-treatment follow-up. Its core product is the Karkinos Platform, a digital-first backbone that binds a Distributed Cancer Care Network (DCCN) of partner hospitals, mobile screening units, and a remote Command Center into a single longitudinal patient record. The platform powers named service lines including Advanced Diagnostics Labs (HPV DNA, KGT, CardioSeq NGS, WGS, pathology), Women's Wellness cervical/breast screening, Early Detection risk-assessment screening, Sequencing-as-a-Service, and Treatment delivered through the partner hospital network.

Product overview

Karkinos Healthcare is a technology-led, purpose-driven oncology platform that operates as a single digital-first product (the Karkinos Platform / Distributed Cancer Care Network) augmented by a portfolio of named modules: Advanced Diagnostics Labs, Women's Wellness, Early Detection, Sequencing-as-a-Service, Karkinos WGS (Whole Genome Sequencing), KGT (Karkinos Genetic Test), CardioSeq (the 223-gene cardiac NGS panel), Treatment via the Karkinos Hospital Network, the Karkinos Command Center, the Karkinos mobile app, the k-Vani content hub, the Expert Opinion second-opinion service, and the CIRP community screening programme. These modules are unified by the Karkinos Platform's digital backbone — a hub-and-spoke Distributed Cancer Care Network that integrates risk assessment, screening, diagnostics, genomic sequencing, chemotherapy, radiation, and molecular tumor boards into a single longitudinal patient record with AI/ML-driven insights, FHIR-based interoperability, and ABHA integration under India's Ayushman Bharat Digital Mission.

Differentiator

Problem solved

Functional benefit

Brands

• K-Vani: Karkinos Healthcare's branded thought-leadership and health-insights content platform hosting articles, whitepapers, podcasts and expert commentary on cancer.
• CIRP

Products and services

• Karkinos Platform (Distributed Cancer Care Network) Technology-led, digital-first oncology backbone that binds the Distributed Cancer Care Network (DCCN) of partner hospitals, mobile screening units, molecular biologists, oncologists, and a remote Command Center into a single longitudinal patient record with AI/ML-driven insights, FHIR-based interoperability, SOC 2 Type 2 compliance, and ABHA/ABDM integration. Sold to hospitals as a commissioning and managed-services stack and operated by Karkinos to deliver end-to-end cancer care.
• Karkinos Advanced Diagnostics Labs Network of CAP-, NABH- and NABL-accredited diagnostic laboratories (Tamil Nadu, Mumbai, Assam, Kerala, Uttar Pradesh) offering personalised advanced diagnostics including molecular and genomic testing, HPV DNA testing, KGT, CardioSeq, WGS, and routine pathology. Billed per test to patients, clinicians and partner hospitals.
• Women's Wellness Program Women-focused cancer screening programme featuring WHO-aligned HPV DNA testing, cervical precancerous lesion screening (VIA, Pap, LBC, HPV testing, colposcopy) and breast cancer screening. Includes the Karkinos rural women outreach model and an online HPV-test booking flow. Sold to individual women, NGOs, CSR programmes and government public-health initiatives.
• Early Detection (Risk-Assessment-Based Screening) Risk-assessment-based early screening programme covering five cancer types, designed to detect cancer at Stage I/II and reduce out-of-pocket expenditure via community-level screening, mobile units and digital follow-up navigation. Sold through camps, partner hospitals and the website.
• Sequencing as a Service Sequencing-as-a-service offering leveraging next-generation sequencing (NGS) and molecular biology capabilities to support clinicians, hospitals and research partners with comprehensive tumour-DNA analysis, delivered through Karkinos's advanced diagnostics labs.
• Karkinos WGS (Whole Genome Sequencing) In-house Whole Genome Sequencing service supporting population-scale, India-specific personalised treatment strategies and used in conjunction with the Bharat Cancer Genome Atlas collaboration. Sold to clinicians, hospitals and research partners.
• KGT (Karkinos Genetic Test) Genetic testing service providing germline and hereditary cancer risk assessment, including BRCA and multi-gene panels for breast, cervical and other hereditary cancers. Sold to individual patients and clinicians as a paid genetic test.
• CardioSeq (223-gene NGS panel for cardiac genetics) Karkinos Healthcare's comprehensive 223-gene Next-Generation Sequencing panel for cardiac genetics, expanding the genomics portfolio beyond oncology. Sold to clinicians and patients as a paid NGS test.
• Treatment (Karkinos Hospital Network) Cancer treatment delivered through Karkinos's partner hospital network, including chemotherapy, radiation, brachytherapy, surgery and post-treatment follow-up navigation, with treatment protocols centrally managed via the Command Center and Karkinos Platform.
• Expert Opinion (Second Opinion Service) Digitally-coordinated second-opinion and teleconsultation service for cancer diagnosis and treatment planning, enabling patients and physicians to obtain expert reviews remotely via expertopinion.live.karkinos.in. Sold to individual patients and clinicians as a paid second-opinion service.
• CIRP (Community Cancer Screening Program) Community-level cancer screening initiative that delivers risk assessment, screening and follow-up navigation to populations outside major hospital catchments, typically via partner NGOs, KareMitras and ASHA-style frontline workers. Sold as community screening contracts to NGOs, CSR programmes and public-health bodies.

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Onco.com: India-headquartered digital oncology platform offering second opinions, tele-oncology consultations and cancer care navigation. Most direct comparable to Karkinos's Expert Opinion / Command Center + remote navigation stack for Indian cancer patients.
• 4baseCare: Indian oncology genomics startup offering NGS-based tumour profiling and molecular diagnostics. Directly comparable to Karkinos's KGT, CardioSeq 223-gene NGS panel and WGS sequencing-as-a-service modules, with overlapping clinician customers in India.
• MedGenome: India- and US-based genomics and diagnostics company offering NGS panels, hereditary cancer testing and rare disease diagnostics. Direct comparable on the KGT / CardioSeq / WGS sequencing-as-a-service line, with overlapping hospital and clinician customers.
• Strand Life Sciences: India-based genomics and bioinformatics company with a hereditary cancer and NGS panel portfolio. Direct comparable to Karkinos's KGT hereditary risk and CardioSeq offerings, and a likely collaborator/competitor in Indian population genomics initiatives.

Emerging players

• Predible Health: India-based AI-powered oncology diagnostics company applying deep learning to radiology and pathology workflows. Overlaps with Karkinos's AI/ML-driven DCCN insights and multimodal clinical-radiology-pathology data integration.
• Niramai Health Analytix: Indian health-tech startup offering AI-based non-invasive breast cancer screening (Thermalytix). Comparable to Karkinos's Women's Wellness / Early Detection risk-assessment screening modules and similar tier-2/3 India go-to-market.

Broad incumbents

• Apollo Hospitals Enterprise: India's largest hospital chain with established oncology programs across multiple cities. Broad incumbent comparable on cancer treatment delivery; competes with Karkinos for the same oncologists and partner hospitals, but operates owned (not asset-light commissioned) centres.
• Fortis Healthcare: Major Indian hospital chain with multi-specialty cancer care. Comparable as a broad incumbent in oncology delivery; one of the established players whose hospitals Karkinos could either partner with or compete against in DCCN expansion.
• Max Healthcare: Leading North India hospital chain with significant oncology footprint. Broad incumbent competing with Karkinos for tertiary cancer cases, particularly in the northern states where Karkinos also operates (UP, Kerala, NE).
• Tata Medical Centre / Tata Memorial Centre: India's premier public cancer hospital and research centre; founded by the Tata Group. Provides the most important competitive benchmark for Karkinos and has supplied several senior clinical leaders (e.g., Director-level staff at Karkinos come from Tata Memorial Centre).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/karkinoshealth
• YouTubeyoutube.com/watch?v=Af2JG5VmnqQ
• Facebookfacebook.com/Karkinoshealthcare
• LinkedInlinkedin.com/company/karkinos-healthcare
• Instagraminstagram.com/karkinoshealthcare

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karkinos Healthcare